更正后的简报-EMA 的 CHMP 建议不授予 Elevidys 治疗杜兴氏肌肉萎缩症的上市许可

路透中文
Jul 25, 2025
更正后的简报-EMA 的 CHMP 建议不授予 Elevidys 治疗杜兴氏肌肉萎缩症的上市许可

更正以修正来源

路透7月25日 -

  • 欧洲药品管理局:建议不授予伊克替尼治疗杜兴氏肌肉萎缩症的上市许可

  • EMA的CHMP:Ekterly在治疗遗传性血管性水肿急性发作方面获得CHMP的肯定意见

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10